Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer
Candel Therapeutics' late-breaking abstract on aglatimagene besadenovec in localized prostate cancer has been accepted for poster presentation at the SITC 41st Annual Meeting, November 4-8, 2026, in Phoenix. The poster will show longitudinal immune-profiling, biodistribution, and viral shedding data from the phase 2 PrTK05 trial in localized intermediate-risk prostate cancer, presented by CSO Francesca Barone on November 7.
Key figures
- Drug Name
- aglatimagene besadenovec
- Phase Of Trial
- Phase 2
- Session date
- November 7, 2026
- Abstract number
- 1172
- Trial registration
- NCT07332000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.